论文部分内容阅读
目的探讨安普贴联合喜疗妥预防化疗患者静脉炎的效果及对患者血清高敏C-反应蛋白(hs-CRP)和白细胞介素-6(IL-6)水平的影响。方法选取2015年9月至2016年9月间上海市同济大学附属肺科医院收治的400例接受化疗的恶性肿瘤患者,采用随机数字表法分为观察组与对照组,每组200例。患者均行常规静脉化疗,对照组患者化疗时在穿刺点上方贴安普贴治疗,观察组患者在对照组基础上沿穿刺静脉走向涂喜辽妥治疗。比较两组患者静脉炎的发生情况、疼痛情况、治疗前后的肝肾功能及血清hs-CRP和IL-6水平的变化情况。结果治疗1周后,观察组患者静脉炎发生情况明显优于对照组(0.5%vs 3.5%),组间比较,差异有统计学意义(P<0.05);两组患者疼痛情况比较(0.0%vs 28.6%),差异无统计学意义(P>0.05)。两组患者治疗后血清hs-CRP(10.35±3.18 vs 13.27±4.25;10.59±3.46 vs 16.30±5.51)和IL-6(5.24±2.17 vs 8.66±2.53;5.57±2.39 vs 11.82±3.77)水平较治疗前均上升,且对照组患者上升更为显著,差异均有统计学意义(均P<0.05)。两组患者治疗前后肝肾功能指标均未发生明显变化,差异均无统计学意义(均P>0.05)。结论恶性肿瘤化疗患者采用安普贴联合喜疗妥预防治疗,能够有效减少静脉炎的发生,且不会影响肝肾功能,有一定的临床价值。
Objective To investigate the effect of Ampressing combined with Hilti on the prevention of phlebitis in patients undergoing chemotherapy and its effect on serum hs-CRP and IL-6 levels. Methods From September 2015 to September 2016, 400 patients with malignant tumor undergoing chemotherapy in Pulmonary Hospital of Tongji University, Shanghai were divided into observation group and control group with 200 cases in each group. All patients underwent routine intravenous chemotherapy. Patients in the control group were treated with APT at the top of the puncture site during the chemotherapy. The patients in the observation group went along the puncture vein to Tu Xiao Liao on the basis of the control group. The incidence of phlebitis, pain, changes in liver and kidney function and serum hs-CRP and IL-6 levels before and after treatment were compared between the two groups. Results The incidence of phlebitis in the observation group was significantly better than that in the control group (0.5% vs 3.5%) after 1 week of treatment. There was significant difference between the two groups (P <0.05) vs 28.6%), the difference was not statistically significant (P> 0.05). The levels of serum hs-CRP (10.35 ± 3.18 vs 13.27 ± 4.25; 10.59 ± 3.46 vs 16.30 ± 5.51) and IL-6 (5.24 ± 2.17 vs 8.66 ± 2.53; 5.57 ± 2.39 vs 11.82 ± 3.77) Before treatment, the patients in the control group rose more significantly, the differences were statistically significant (all P <0.05). There was no significant difference between the two groups before and after treatment of liver and kidney function indicators, the difference was not statistically significant (P> 0.05). Conclusions The patients with malignant tumor chemotherapy treated with Amplicon combined with Hilti should prevent and cure phlebitis effectively without affecting the function of liver and kidney and have certain clinical value.